Published on : Sep 15, 2017
Albany, New York, September 15, 2017: In recent past, there has been a rapid rise in hereditary angioedema (HAE) attacks. Owing to the rarity of the disease, there is lack of awareness among patients and physicians which have resulted in unmet diagnosis of the disease and in turn mismanagement of the disease. With progress in the diagnostic field and different initiatives undertaken by patient bodies and industry players to spread awareness, the market for hereditary angioedema is projected to grow, finds a new study broadcasted to the wide repository of Market Research Hub (MRH). The study is titled as “Hereditary Angioedema Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025” which presents the comprehensive evaluation of the market by presenting market trends and forecasts till 2025. In addition, the market size estimations have been provided in terms of volume and value (USD million).
For a clear understanding of the market, the report studies the current as well as future prospects of the market globally. In order to explain the intensity of competition in the market, the report has been segmented geographically into major regions including North America, Europe, Asia Pacific and RoW. In the first part, the market overview section of the report explores the market dynamics such as drivers, restraints and opportunities that currently have a strong impact on the hereditary angioedema market and could influence the market in the near future. In terms of geography, North America, of them, is the leading region which is projected to rise at a healthy CAGR of 8.3% from 2017 to 2025
Hereditary angioedema is a rare disease and is mostly mistaken for common allergic reactions and abdominal pain. It is caused by lack or abnormal functioning of the protein C1 inhibitor protein. Lack of functional C1 inhibitor protein leads to high volume of bradykinin, which triggers of blood vessels causing inflammation of body organs. It has been also analyzed that Hereditary Angioedema may be acquired or inherited; it is predominant in children. With increasing awareness about the disease and introduction of novel drugs for treatment, global hereditary angioedema market is projected to grow and will likely become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016 by recording a strong 9.1% CAGR from 2017 to 2025. It is estimated that around 40% of the affected patient are diagnosed correctly for HAE in the U.S. and Europe.
Moreover, the study highlights overall information and data analysis of the global hereditary angioedema market with respect to the leading market segments based on drug classes, route of administration, distribution channel and above-mentioned geographies. Drug classes analyzed in the study are C1 esterase inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor others. Amongst, the C1 esterase inhibitor segment is anticipated to hold a significant share of the global market. Based on route of administration, the global hereditary angioedema market is segmented into intravenous, subcutaneous injections and oral. Major distribution channels are hospital pharmacies, retail pharmacies and others.
Key companies profiled in the report include Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc. and iBio, Inc.
Request a Sample with TOC in a PDF format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1320919
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com